Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC
Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC
Recruiting · NCT07281716 · Registry updated 2026-02-19Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 1 / Phase 2 | 2026-02-19 | NCT07281716 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Cantargia AB | 2 |
| Coherus Oncology, Inc. | 14 |
| Dan Feng | 2 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Icahn School of Medicine at Mount Sinai | New York | United States | 342 |